Second, glycine is added to the C-terminal of gamma-glutamylcysteine. This condensation is catalyzed by glutathione synthetase.
While all animal cells are capable of synthesizing glutathione, glutathione synthesis in the liver has been shown to be essential. GCLC knockout mice die within a month of birth due to the absence of hepatic GSH synthesis.
The unusual gamma amide linkage in glutathione protects it from hydrolysis by peptidases.
Glutathione is the most abundant thiol in animal cells, ranging from 0.5 to 10 mM. It is present in the cytosol and the organelles.
Glutathione exists in reduced (GSH) and oxidized (GSSG) states. The ratio of reduced glutathione to oxidized glutathione within cells is a measure of cellular oxidative stress where increased GSSG-to-GSH ratio is indicative of greater oxidative stress. In healthy cells and tissue, more than 90% of the total glutathione pool is in the reduced form (GSH), with the remainder in the disulfide form (GSSG).
Aside from deactivating radicals and reactive oxidants, glutathione participates in thiol protection and redox regulation of cellular thiol proteins under oxidative stress by protein S-glutathionylation, a redox-regulated post-translational thiol modification. The general reaction involves formation of an unsymmetrical disulfide from the protectable protein (RSH) and GSH:
RSH + GSH + [O] → GSSR + H2O
Glutathione is also employed for the detoxification of methylglyoxal and formaldehyde, toxic metabolites produced under oxidative stress. This detoxification reaction is carried out by the glyoxalase system. Glyoxalase I (EC 184.108.40.206) catalyzes the conversion of methylglyoxal and reduced glutathione to S-D-lactoyl-glutathione. Glyoxalase II (EC 220.127.116.11) catalyzes the hydrolysis of S-D-lactoyl-glutathione to glutathione and D-lactic acid.
It maintains exogenous antioxidants such as vitamins C and E in their reduced (active) states.
Systemic bioavailability of orally consumed glutathione is poor because the tripeptide is the substrate of proteases (peptidases) of the alimentary canal, and due to the absence of a specific carrier of glutathione at the level of cell membrane.
In another study, researchers reported long term glutathione supplementation offers protection from oxidative damage. In this study 500 mg oral GSH supplementation not only increased erythrocytic GSH but also decreased 8-OHdG significantly within three months in elderly (age above 55 years) diabetic individuals
Because direct supplementation of glutathione is not successful, supply of the raw nutritional materials used to generate GSH, such as acetylcysteine and glycine, may be more effective at increasing glutathione levels. Other antioxidants such as ascorbic acid (vitamin C) may also work synergistically with glutathione, preventing depletion of either. The glutathione-ascorbate cycle, which works to detoxify hydrogen peroxide (H2O2), is one very specific example of this phenomenon.
Compounds such as N-acetylcysteine (NAC) and alpha lipoic acid (ALA, not to be confused with the unrelated alpha-linolenic acid) are both capable of helping to regenerate glutathione levels. NAC in particular is commonly used to treat overdose of acetaminophen, a type of potentially fatal poisoning which is harmful in part due to severe depletion of glutathione levels. It is a precursor of cysteine.
Calcitriol (1,25-dihydroxyvitamin D3), the active metabolite of vitamin D3, after being synthesized from calcifediol in the kidney, increases glutathione levels in the brain and appears to be a catalyst for glutathione production. About ten days are needed for the body to process vitamin D3 into calcitriol.
S-adenosylmethionine (SAMe), a cosubstrate involved in methyl group transfer, has also been shown to increase cellular glutathione content in persons suffering from a disease-related glutathione deficiency.
Low glutathione is commonly observed in wasting and negative nitrogen balance, as seen in cancer, HIV/AIDS, sepsis, trauma, burns, and athletic overtraining. Low levels are also observed in periods of starvation. These effects are hypothesized to be influenced by the higher glycolytic activity associated with cachexia, which result from reduced levels of oxidative phosphorylation.
Determination of glutathioneEdit
Ellman's reagent and monobromobimaneEdit
Reduced glutathione may be visualized using Ellman's reagent or bimane derivatives such as monobromobimane. The monobromobimane method is more sensitive. In this procedure, cells are lysed and thiols extracted using a HClbuffer. The thiols are then reduced with dithiothreitol and labelled by monobromobimane. Monobromobimane becomes fluorescent after binding to GSH. The thiols are then separated by HPLC and the fluorescence quantified with a fluorescence detector.
Using monochlorobimane, the quantification is done by confocal laser scanning microscopy after application of the dye to living cells. This quantification process relies on measuring the rates of fluorescence changes and is limited to plant cells.
CMFDA has also been mistakenly used as a glutathione probe. Unlike monochlorobimane, whose fluorescence increases upon reacting with glutathione, the fluorescence increase of CMFDA is due to the hydrolysis of the acetate groups inside cells. Although CMFDA may react with glutathione in cells, the fluorescence increase does not reflect the reaction. Therefore, studies using CMFDA as a glutathione probe should be revisited and reinterpreted.
The major limitation of these bimane-based probes and many other reported probes is that these probes are based on irreversible chemical reactions with glutathione, which renders these probes incapable of monitoring the real-time glutathione dynamics. Recently, the first reversible reaction based fluorescent probe-ThiolQuant Green (TQG)-for glutathione was reported. ThiolQuant Green can not only perform high resolution measurements of glutathione levels in single cells using a confocal microscope, but also be applied in flow cytometry to perform bulk measurements.
The RealThiol (RT) probe is a second-generation reversible reaction-based GSH probe. A few key features of RealThiol: 1) it has a much faster forward and backward reaction kinetics compared to ThiolQuant Green, which enables real-time monitoring of GSH dynamics in live cells; 2) only micromolar to sub-micromolar RealThiol is needed for staining in cell-based experiments, which induces minimal perturbation to GSH level in cells; 3) a high-quantum-yield coumarin fluorophore was implemented so that background noise can be minimized; and 4) equilibrium constant of the reaction between RealThiol and GSH has been fine-tuned to respond to physiologically relevant concentration of GSH. RealThiol can be used to perform measurements of glutathione levels in single cells using a high-resolution confocal microscope, as well as be applied in flow cytometry to perform bulk measurements in high throughput manner.
Organelle-targeted RT probe has also been developed. A mitochondria targeted version, MitoRT, was reported and demonstrated in monitoring the dynamic of mitochondrial glutathione both on confocoal microscope and FACS based analysis.
Protein-based glutathione probesEdit
Another approach, which allows measurement of the glutathione redox potential at a high spatial and temporal resolution in living cells, is based on redox imaging using the redox-sensitive green fluorescent protein (roGFP) or redox-sensitive yellow fluorescent protein (rxYFP).
Because its very low physiological concentration, GSSG is difficult to measure accurately. GSSG concentration ranges from 10 to 50 μM in all solid tissues, and from 2 to 5 μM in blood (13–33 nmol per gram Hb). GSH-to-GSSG ratio of whole cell extracts is estimated from 100 to 700. Those ratios represent a mixture from the glutathione pools of different redox states from different subcellular compartments (e.g. more oxidized in the ER, more reduced in the mitochondrial matrix), however. In vivo GSH-to-GSSG ratios can be measured with subcellular accuracy using fluorescent protein-based redox sensors, which have revealed ratios from 50,000 to 500,000 in the cytosol, which implies that GSSG concentration is maintained in the pM range.
Once a tumor has been established, elevated levels of glutathione may act to protect cancerous cells by conferring resistance to chemotherapeutic drugs. The antineoplastic mustard drug canfosfamide was modeled on the structure of glutathione.
Several studies have been completed on the effectiveness of introducing inhaled glutathione to people with cystic fibrosis with mixed results.
Although extracellular amyloid beta (Aβ) plaques, neurofibrillary tangles (NFT), inflammation in the form of reactive astrocytes and microglia, and neuronal loss are consistent pathological features of Alzheimer's disease (AD), a mechanistic link between these factors is not clear. Although the majority of past research has focused on fibrillar Aβ, soluble oligomeric Aβ species are now considered to be of major pathological importance in AD. Upregulation of GSH may be protective against the oxidative and neurotoxic effects of oligomeric Aβ.[medical citation needed]
Depletion of the closed form of GSH in the hippocampus may be a potential early diagnostic biomarker for AD.
Glutathione is the most common agent taken by mouth in an attempt to whiten the skin. It may also be used as a cream. Whether or not it actually works is unclear as of 2019. Due to side effects that may result with intravenous use, the government of the Philippines recommends against such use.
^Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF (October 2003). "The changing faces of glutathione, a cellular protagonist". Biochemical Pharmacology. 66 (8): 1499–503. doi:10.1016/S0006-2952(03)00504-5. PMID14555227.
^Chen Y, Yang Y, Miller ML, Shen D, Shertzer HG, Stringer KF, Wang B, Schneider SN, Nebert DW, Dalton TP (May 2007). "Hepatocyte-specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure". Hepatology. 45 (5): 1118–28. doi:10.1002/hep.21635. PMID17464988. S2CID 25000753.
^Sies H (1999). "Glutathione and its role in cellular functions". Free Radical Biology & Medicine. 27 (9–10): 916–21. doi:10.1016/S0891-5849(99)00177-X. PMID10569624.
^ abcGuoyao Wu; Yun-Zhong Fang; Sheng Yang; Joanne R. Lupton; Nancy D. Turner (2004). "Glutathione Metabolism and its Implications for Health". Journal of Nutrition. 134 (3): 489–92. doi:10.1093/jn/134.3.489. PMID14988435.
^Copley SD, Dhillon JK (29 April 2002). "Lateral gene transfer and parallel evolution in the history of glutathione biosynthesis genes". Genome Biology. 3 (5): research0025. doi:10.1186/gb-2002-3-5-research0025. PMC115227. PMID12049666.
^Wonisch W, Schaur RJ (2001). "Chapter 2: Chemistry of Glutathione". In Grill D, Tausz T, De Kok L (eds.). Significance of glutathione in plant adaptation to the environment. Springer. ISBN 978-1-4020-0178-9 – via Google Books.
^Pastore A, Piemonte F, Locatelli M, Lo Russo A, Gaeta LM, Tozzi G, Federici G (August 2001). "Determination of blood total, reduced, and oxidized glutathione in pediatric subjects". Clinical Chemistry. 47 (8): 1467–9. doi:10.1093/clinchem/47.8.1467. PMID11468240.
^Lu SC (May 2013). "Glutathione synthesis". Biochimica et Biophysica Acta (BBA) - General Subjects. 1830 (5): 3143–53. doi:10.1016/j.bbagen.2012.09.008. PMC3549305. PMID22995213.
^Halprin KM, Ohkawara A (1967). "The measurement of glutathione in human epidermis using glutathione reductase". The Journal of Investigative Dermatology. 48 (2): 149–52. doi:10.1038/jid.1967.24. PMID6020678.
^Couto N, Malys N, Gaskell SJ, Barber J (June 2013). "Partition and turnover of glutathione reductase from Saccharomyces cerevisiae: a proteomic approach". Journal of Proteome Research. 12 (6): 2885–94. doi:10.1021/pr4001948. PMID23631642.
^Michael Brownlee (2005). "The pathobiology of diabetic complications: A unifying mechanism". Diabetes. 54 (6): 1615–25. doi:10.2337/diabetes.54.6.1615. PMID15919781.
^Dalle-Donne, Isabella; Rossi, Ranieri; Colombo, Graziano; Giustarini, Daniela; Milzani, Aldo (2009). "Protein S-glutathionylation: a regulatory device from bacteria to humans". Trends in Biochemical Sciences. 34 (2): 85–96. doi:10.1016/j.tibs.2008.11.002. PMID19135374.
^Dringen R (December 2000). "Metabolism and functions of glutathione in brain". Progress in Neurobiology. 62 (6): 649–71. doi:10.1016/s0301-0082(99)00060-x. PMID10880854. S2CID 452394.
^Scholz, RW. Graham KS. Gumpricht E. Reddy CC. (1989). "Mechanism of interaction of vitamin E and glutathione in the protection against membrane lipid peroxidation". Ann NY Acad Sci. 570 (1): 514–7. Bibcode:1989NYASA.570..514S. doi:10.1111/j.1749-6632.1989.tb14973.x. S2CID 85414084.
^Hughes RE (1964). "Reduction of dehydroascorbic acid by animal tissues". Nature. 203 (4949): 1068–9. Bibcode:1964Natur.203.1068H. doi:10.1038/2031068a0. PMID14223080. S2CID 4273230.
^Ha SB, Smith AP, Howden R, Dietrich WM, Bugg S, O'Connell MJ, Goldsbrough PB, Cobbett CS (June 1999). "Phytochelatin synthase genes from Arabidopsis and the yeast Schizosaccharomyces pombe". The Plant Cell. 11 (6): 1153–64. doi:10.1105/tpc.11.6.1153. JSTOR 3870806. PMC144235. PMID10368185.
^Grant CM (2001). "Role of the glutathione/glutaredoxin and thioredoxin systems in yeast growth and response to stress conditions". Molecular Microbiology. 39 (3): 533–41. doi:10.1046/j.1365-2958.2001.02283.x. PMID11169096. S2CID 6467802.
^Hayes, John D.; Flanagan, Jack U.; Jowsey, Ian R. (2005). "Glutathione transferases". Annual Review of Pharmacology and Toxicology. 45: 51–88. doi:10.1146/annurev.pharmtox.45.120403.095857. PMID15822171.
^Steullet P, Neijt HC, Cuénod M, Do KQ (February 2006). "Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia". Neuroscience. 137 (3): 807–19. doi:10.1016/j.neuroscience.2005.10.014. PMID16330153. S2CID 1417873.
^ abVarga V, Jenei Z, Janáky R, Saransaari P, Oja SS (September 1997). "Glutathione is an endogenous ligand of rat brain N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors". Neurochemical Research. 22 (9): 1165–71. doi:10.1023/A:1027377605054. PMID9251108. S2CID 24024090.
^Janáky R, Ogita K, Pasqualotto BA, Bains JS, Oja SS, Yoneda Y, Shaw CA (September 1999). "Glutathione and signal transduction in the mammalian CNS". Journal of Neurochemistry. 73 (3): 889–902. doi:10.1046/j.1471-4159.1999.0730889.x. PMID10461878.
^Oja SS, Janáky R, Varga V, Saransaari P (2000). "Modulation of glutamate receptor functions by glutathione". Neurochemistry International. 37 (2–3): 299–306. doi:10.1016/S0197-0186(00)00031-0. PMID10812215. S2CID 44380765.
^Freitas HR, Ferraz G, Ferreira GC, Ribeiro-Resende VT, Chiarini LB, do Nascimento JL, Matos Oliveira KR, Pereira Tde L, Ferreira LG, Kubrusly RC, Faria RX, Herculano AM, Reis RA (14 April 2016). "Glutathione-Induced Calcium Shifts in Chick Retinal Glial Cells". PLOS ONE. 11 (4): e0153677. Bibcode:2016PLoSO..1153677F. doi:10.1371/journal.pone.0153677. PMC4831842. PMID27078878.
^Freitas HR, Reis RA (1 January 2017). "Glutathione induces GABA release through P2X7R activation on Müller glia". Neurogenesis. 4 (1): e1283188. doi:10.1080/23262133.2017.1283188. PMC5305167. PMID28229088.
^Noctor G, Foyer CH (June 1998). "Ascorbate and Glutathione: Keeping Active Oxygen Under Control". Annual Review of Plant Physiology and Plant Molecular Biology. 49 (1): 249–279. doi:10.1146/annurev.arplant.49.1.249. PMID15012235.
^Ha SB, Smith AP, Howden R, Dietrich WM, Bugg S, O'Connell MJ, Goldsbrough PB, Cobbett CS (June 1999). "Phytochelatin synthase genes from Arabidopsis and the yeast Schizosaccharomyces pombe". The Plant Cell. 11 (6): 1153–64. doi:10.1105/tpc.11.6.1153. PMC144235. PMID10368185.
^Parisy V, Poinssot B, Owsianowski L, Buchala A, Glazebrook J, Mauch F (January 2007). "Identification of PAD2 as a gamma-glutamylcysteine synthetase highlights the importance of glutathione in disease resistance of Arabidopsis" (PDF). The Plant Journal. 49 (1): 159–72. doi:10.1111/j.1365-313X.2006.02938.x. PMID17144898.
^Rouhier N, Lemaire SD, Jacquot JP (2008). "The role of glutathione in photosynthetic organisms: emerging functions for glutaredoxins and glutathionylation". Annual Review of Plant Biology. 59 (1): 143–66. doi:10.1146/annurev.arplant.59.032607.092811. PMID18444899.
^Allen J, Bradley RD (September 2011). "Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers". Journal of Alternative and Complementary Medicine. 17 (9): 827–33. doi:10.1089/acm.2010.0716. PMC3162377. PMID21875351.
^Witschi A, Reddy S, Stofer B, Lauterburg BH (1992). "The systemic availability of oral glutathione". European Journal of Clinical Pharmacology. 43 (6): 667–9. doi:10.1007/bf02284971. PMID1362956. S2CID 27606314.
^MedRxiv (29 April 2021). "Randomised clinical trial of long term glutathione supplementation offers protection from oxidative damage, improves HbA1c in elderly type 2 diabetic patients". medRxiv. doi:10.1101/2021.04.27.21256157. S2CID 233445690. Retrieved 28 May 2021.
^Kumar, P; Liu, C; Hsu, JW; Chacko, S; Minard, C; Jahoor, F; Sekhar, RV (March 2021). "Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial". Clinical and translational medicine. 11 (3): e372. doi:10.1002/ctm2.372. PMID33783984.
^Zarka, Martin Hani; Bridge, Wallace John (2017). "Oral administration of γ-glutamylcysteine increases intracellular glutathione levels above homeostasis in a randomised human trial pilot study". Redox Biology. 11: 631–636. doi:10.1016/j.redox.2017.01.014. PMC5284489. PMID28131081.
^"Acetylcysteine Monograph for Professionals". Drugs.com.
^Zhang J, Zhou X, Wu W, Wang J, Xie H, Wu Z (2017). "Regeneration of glutathione by α-lipoic acid via Nrf2/ARE signaling pathway alleviates cadmium-induced HepG2 cell toxicity". Environ Toxicol Pharmacol. 51: 30–37. doi:10.1016/j.etap.2017.02.022. PMID28262510.
^Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D (April 2002). "New clues about vitamin D functions in the nervous system". Trends in Endocrinology and Metabolism. 13 (3): 100–5. doi:10.1016/S1043-2760(01)00547-1. PMID11893522. S2CID 19010892.
^van Groningen L, Opdenoordt S, van Sorge A, Telting D, Giesen A, de Boer H (April 2010). "Cholecalciferol loading dose guideline for vitamin D-deficient adults". European Journal of Endocrinology. 162 (4): 805–11. doi:10.1530/EJE-09-0932. PMID20139241.
^Lieber CS (November 2002). "S-adenosyl-L-methionine: its role in the treatment of liver disorders". The American Journal of Clinical Nutrition. 76 (5): 1183S–7S. doi:10.1093/ajcn/76.5.1183s. PMID12418503.
^Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, Salerno MT, Carrieri V, Albano O (May 1989). "Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease". Scandinavian Journal of Gastroenterology. 24 (4): 407–15. doi:10.3109/00365528909093067. PMID2781235.
^Loguercio C, Nardi G, Argenzio F, Aurilio C, Petrone E, Grella A, Del Vecchio Blanco C, Coltorti M (September 1994). "Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease". Alcohol and Alcoholism. 29 (5): 597–604. doi:10.1093/oxfordjournals.alcalc.a045589. PMID7811344.
^Dröge W, Holm E (November 1997). "Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction". FASEB Journal. 11 (13): 1077–89. doi:10.1096/fasebj.11.13.9367343. PMID9367343. S2CID 17607571.
^Tateishi N, Higashi T, Shinya S, Naruse A, Sakamoto Y (January 1974). "Studies on the regulation of glutathione level in rat liver". Journal of Biochemistry. 75 (1): 93–103. doi:10.1093/oxfordjournals.jbchem.a130387. PMID4151174.
^Meyer AJ, May MJ, Fricker M (July 2001). "Quantitative in vivo measurement of glutathione in Arabidopsis cells". The Plant Journal. 27 (1): 67–78. doi:10.1046/j.1365-313x.2001.01071.x. PMID11489184. S2CID 21015139.
^Sebastià J, Cristòfol R, Martín M, Rodríguez-Farré E, Sanfeliu C (January 2003). "Evaluation of fluorescent dyes for measuring intracellular glutathione content in primary cultures of human neurons and neuroblastoma SH-SY5Y". Cytometry. Part A. 51 (1): 16–25. doi:10.1002/cyto.a.10003. PMID12500301. S2CID 24681280.
^Lantz RC, Lemus R, Lange RW, Karol MH (April 2001). "Rapid reduction of intracellular glutathione in human bronchial epithelial cells exposed to occupational levels of toluene diisocyanate". Toxicological Sciences. 60 (2): 348–55. doi:10.1093/toxsci/60.2.348. PMID11248147.
^Jiang X, Yu Y, Chen J, Zhao M, Chen H, Song X, Matzuk AJ, Carroll SL, Tan X, Sizovs A, Cheng N, Wang MC, Wang J (March 2015). "Quantitative imaging of glutathione in live cells using a reversible reaction-based ratiometric fluorescent probe". ACS Chemical Biology. 10 (3): 864–74. doi:10.1021/cb500986w. PMC4371605. PMID25531746.
^Jiang X, Chen J, Bajić A, Zhang C, Song X, Carroll SL, Cai ZL, Tang M, Xue M, Cheng N, Schaaf CP, Li F, MacKenzie KR, Ferreon AC, Xia F, Wang MC, Maletić-Savatić M, Wang J (July 2017). "Quantitative imaging of glutathione". Nature Communications. 8: 16087. doi:10.1038/ncomms16087. PMC5511354. PMID28703127.
^Chen J, Jiang X, Zhang C, MacKenzie KR, Stossi F, Palzkill T, Wang MC, Wang J (2017). "Reversible Reaction-Based Fluorescent Probe for Real-Time Imaging of Glutathione Dynamics in Mitochondria". ACS Sensors. 2 (9): 1257–1261. doi:10.1021/acssensors.7b00425. PMC5771714. PMID28809477.
^Meyer AJ, Brach T, Marty L, Kreye S, Rouhier N, Jacquot JP, Hell R (December 2007). "Redox-sensitive GFP in Arabidopsis thaliana is a quantitative biosensor for the redox potential of the cellular glutathione redox buffer". The Plant Journal. 52 (5): 973–86. doi:10.1111/j.1365-313X.2007.03280.x. PMID17892447.
^Maulucci G, Labate V, Mele M, Panieri E, Arcovito G, Galeotti T, Østergaard H, Winther JR, De Spirito M, Pani G (October 2008). "High-resolution imaging of redox signaling in live cells through an oxidation-sensitive yellow fluorescent protein". Science Signaling. 1 (43): pl3. doi:10.1126/scisignal.143pl3. PMID18957692. S2CID 206670068.
^Giustarini D, Dalle-Donne I, Milzani A, Fanti P, Rossi R (September 2013). "Analysis of GSH and GSSG after derivatization with N-ethylmaleimide". Nature Protocols. 8 (9): 1660–9. doi:10.1038/nprot.2013.095. PMID23928499. S2CID 22645510.
^Schwarzländer M, Dick T, Meyer AJ, Morgan B (April 2016). "Dissecting Redox Biology Using Fluorescent Protein Sensors". Antioxidants & Redox Signaling. 24 (13): 680–712. doi:10.1089/ars.2015.6266. PMID25867539.
^Dröge, Wulf; Breitkreutz, Raoul (2000). "Glutathione and immune function". Proceedings of the Nutrition Society. 59 (4): 595–600. doi:10.1017/S0029665100000847. ISSN 0029-6651. PMID11115795.
^Exner, R.; Wessner, B.; Manhart, N.; Roth, E. (28 July 2000). "Therapeutic potential of glutathione". Wiener Klinische Wochenschrift. 112 (14): 610–616. ISSN 0043-5325. PMID11008322.
^Lang, Calvin A. (2001). "The Impact of Glutathione on Health and Longevity". Journal of Anti-Aging Medicine. 4 (2): 137–144. doi:10.1089/10945450152466189. ISSN 1094-5458.
^Townsend, Danyelle M.; Tew, Kenneth D.; Tapiero, Haim (2003). "The importance of glutathione in human disease". Biomedicine & Pharmacotherapy. 57 (3–4): 145–155. doi:10.1016/S0753-3322(03)00043-X. PMC6522248. PMID12818476.
^Wu, Guoyao; Fang, Yun-Zhong; Yang, Sheng; Lupton, Joanne R.; Turner, Nancy D. (1 March 2004). "Glutathione Metabolism and Its Implications for Health". The Journal of Nutrition. 134 (3): 489–492. doi:10.1093/jn/134.3.489. ISSN 0022-3166. PMID14988435.
^Franco, R.; Schoneveld, O. J.; Pappa, A.; Panayiotidis, M. I. (2007). "The central role of glutathione in the pathophysiology of human diseases". Archives of Physiology and Biochemistry. 113 (4–5): 234–258. doi:10.1080/13813450701661198. ISSN 1381-3455. PMID18158646. S2CID 35240599.
^Ballatori, Nazzareno; Krance, Suzanne M.; Notenboom, Sylvia; Shi, Shujie; Tieu, Kim; Hammond, Christine L. (1 March 2009). "Glutathione dysregulation and the etiology and progression of human diseases". Biological Chemistry. 390 (3): 191–214. doi:10.1515/BC.2009.033. ISSN 1437-4315. PMC2756154. PMID19166318.
^Forman, Henry Jay; Zhang, Hongqiao; Rinna, Alessandra (2009). "Glutathione: Overview of its protective roles, measurement, and biosynthesis". Molecular Aspects of Medicine. 30 (1–2): 1–12. doi:10.1016/j.mam.2008.08.006. PMC2696075. PMID18796312.
^Pizzorno, Joseph E.; Katzinger, Joseph J. (1 September 2012). "Glutathione: Physiological and Clinical Relevance". Journal of Restorative Medicine. 1 (1): 24–37. doi:10.14200/jrm.2012.1.1002. ISSN 2165-7971.
^Teskey, Garrett; Abrahem, Rachel; Cao, Ruoqiong; Gyurjian, Karo; Islamoglu, Hicret; Lucero, Mariana; Martinez, Andrew; Paredes, Erik; Salaiz, Oscar (2018), "Glutathione as a Marker for Human Disease", Advances in Clinical Chemistry, Elsevier, 87: 141–159, doi:10.1016/bs.acc.2018.07.004, ISBN 978-0-12-815203-4, PMID30342710
^Balendiran GK, Dabur R, Fraser D (2004). "The role of glutathione in cancer". Cell Biochemistry and Function. 22 (6): 343–52. doi:10.1002/cbf.1149. PMID15386533. S2CID 26950450.
^Visca A, Bishop CT, Hilton SC, Hudson VM (2008). "Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study". Journal of Cystic Fibrosis. 7 (5): 433–6. doi:10.1016/j.jcf.2008.03.006. PMID18499536.
^Bishop C, Hudson VM, Hilton SC, Wilde C (January 2005). "A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis". Chest. 127 (1): 308–17. doi:10.1378/chest.127.1.308. PMID15653998.
^Mandal PK, Tripathi M, Sugunan S (January 2012). "Brain oxidative stress: detection and mapping of anti-oxidant marker 'Glutathione' in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy". Biochemical and Biophysical Research Communications. 417 (1): 43–48. doi:10.1016/j.bbrc.2011.11.047. PMID22120629.
^Mandal PK, Saharan, S, Tripathi M, Murari G (October 2015). "Brain Glutathione Levels – A Novel Biomarker for Mild Cognitive Impairment and Alzheimer's Disease". Biological Psychiatry. 78 (10): 702–710. doi:10.1016/j.biopsych.2015.04.005. PMID26003861. S2CID 10187959.
^Vallverdú-Queralt A, Verbaere A, Meudec E, Cheynier V, Sommerer N (January 2015). "Straightforward method to quantify GSH, GSSG, GRP, and hydroxycinnamic acids in wines by UPLC-MRM-MS". Journal of Agricultural and Food Chemistry. 63 (1): 142–9. doi:10.1021/jf504383g. PMID25457918.
^ abMalathi, M; Thappa, DM (2013). "Systemic skin whitening/lightening agents: what is the evidence?". Indian Journal of Dermatology, Venereology and Leprology. 79 (6): 842–6. doi:10.4103/0378-6323.120752. PMID24177629.
^Dilokthornsakul, W; Dhippayom, T; Dilokthornsakul, P (June 2019). "The clinical effect of glutathione on skin color and other related skin conditions: A systematic review". Journal of Cosmetic Dermatology. 18 (3): 728–737. doi:10.1111/jocd.12910. PMID30895708. S2CID 84842395.
^Sonthalia, Sidharth; Daulatabad, Deepashree; Sarkar, Rashmi (2016). "Glutathione as a skin whitening agent: Facts, myths, evidence and controversies". Indian J. Dermatol. Venereol. Leprol. 82 (3): 262–72. doi:10.4103/0378-6323.179088. PMID27088927.
Bilinsky LM, Reed MC, Nijhout HF (July 2015). "The role of skeletal muscle in liver glutathione metabolism during acetaminophen overdose". Journal of Theoretical Biology. 376: 118–33. doi:10.1016/j.jtbi.2015.04.006. PMC4431659. PMID25890031.
Robin A. Smith (24 June 2015). "Model Could Help Counteract Poisoning from Popular Painkiller". ALN.
Drevet JR (May 2006). "The antioxidant glutathione peroxidase family and spermatozoa: a complex story". Molecular and Cellular Endocrinology. 250 (1–2): 70–9. doi:10.1016/j.mce.2005.12.027. PMID16427183. S2CID 27303332.
Wu G, Fang YZ, Yang S, Lupton JR, Turner ND (March 2004). "Glutathione metabolism and its implications for health". The Journal of Nutrition. 134 (3): 489–92. doi:10.1093/jn/134.3.489. PMID14988435.